Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients

There are limited data regarding the feasibility of transitioning from intravenous prostacyclins to selexipag in pulmonary arterial hypertension patients. We present a case series of successful transitions from intravenous prostacyclins to selexipag in the majority of carefully selected five stable...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pulmonary circulation 2021-10, Vol.11 (4), p.1-5, Article 20458940211036623
Hauptverfasser:	Aldweib, Nael, Verlinden, Nathan J., Kassis-George, Hayah, Raina, Amresh
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardiac & Cardiovascular Systems Cardiovascular System & Cardiology Case Report Life Sciences & Biomedicine pulmonary arterial hypertension Pulmonary hypertension pulmonary vasodilators Respiratory System Science & Technology the United States Registry to Evaluate Early and Long‐term PAH disease management (REVEAL)
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	There are limited data regarding the feasibility of transitioning from intravenous prostacyclins to selexipag in pulmonary arterial hypertension patients. We present a case series of successful transitions from intravenous prostacyclins to selexipag in the majority of carefully selected five stable pulmonary arterial hypertension patients using a standardized protocol in the outpatient setting.
ISSN:	2045-8940 2045-8932 2045-8940
DOI:	10.1177/20458940211036623